MedTrace Logo

Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

NCT04663438 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-12-11

No results posted yet for this study

Summary

The study is a prospective,multi-center,single arm,real world study to evaluate safety and performance of Atezolizumab plus chemotherapy in patients with extensive-stage small-cell lung cancer,and also to explore potential biomarkers for Immune-related Adverse Events.

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Chemotherapy Drugs, Cancer

Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Beijing Chest Hospital

    collaborator OTHER

  • Beijing Chao Yang Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Li Zhang, PhD · Peking union medical college hospital,China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2020-12-30
Completion
2021-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04663438 on ClinicalTrials.gov